A Randomized Phase 2 Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-Line Therapy for EGFR-Negative NSCLC (ALTER-L018)-MedSci.cn - williamhill asia

A Randomized Phase 2 Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-Line Therapy for EGFR-Negative NSCLC (ALTER-L018)

Wu, L; Wu, Z; Xiao, Z; Weng, J; Xiao, M; Ma, Z; Chen, Y; Zhang, H; Cao, Y; Duan, H; Cao, P; Wang, Q; Li, J; Xu, Y; Pu, X; Li, K

JOURNAL OF THORACIC ONCOLOGY, 2021; 16 (3): S596

科室
- - 订阅+
  - 更多科室
工具
服务